177 related articles for article (PubMed ID: 22527313)
1. The subconjunctival use of cetuximab and bevacizumab in inhibition of corneal angiogenesis.
Tunik S; Nergiz Y; Keklikci U; Akkus M
Graefes Arch Clin Exp Ophthalmol; 2012 Aug; 250(8):1161-7. PubMed ID: 22527313
[TBL] [Abstract][Full Text] [Related]
2. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA
Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599
[TBL] [Abstract][Full Text] [Related]
3. Effects of subconjunctivally injected bevacizumab, etanercept, and the combination of both drugs on experimental corneal neovascularization.
Ozdemir O; Altintas O; Altintas L; Yildiz DK; Sener E; Caglar Y
Can J Ophthalmol; 2013 Apr; 48(2):115-20. PubMed ID: 23561605
[TBL] [Abstract][Full Text] [Related]
4. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.
Hurmeric V; Mumcuoglu T; Erdurman C; Kurt B; Dagli O; Durukan AH
Cornea; 2008 Apr; 27(3):357-62. PubMed ID: 18362668
[TBL] [Abstract][Full Text] [Related]
5. Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits.
Yoo AR; Chung SK
Cornea; 2014 Oct; 33(10):1088-94. PubMed ID: 25119962
[TBL] [Abstract][Full Text] [Related]
6. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.
Öner V; Küçükerdönmez C; Akova YA; Çolak A; Karalezli A
Ophthalmic Res; 2012; 48(3):118-23. PubMed ID: 22538642
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of corneal neovascularization by subconjunctival and topical bevacizumab and sunitinib in a rabbit model.
Ko BY; Kim YS; Baek SG; Lee GW; Kim JM; Jean WS; Lee NS; Kang J
Cornea; 2013 May; 32(5):689-95. PubMed ID: 23377751
[TBL] [Abstract][Full Text] [Related]
8. The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea.
Barros LF; Belfort R
An Acad Bras Cienc; 2007 Sep; 79(3):389-94. PubMed ID: 17768531
[TBL] [Abstract][Full Text] [Related]
9. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.
Sener E; Yuksel N; Yildiz DK; Yilmaz B; Ozdemir O; Caglar Y; Degirmenci E
Curr Eye Res; 2011 Nov; 36(11):1005-13. PubMed ID: 21999227
[TBL] [Abstract][Full Text] [Related]
10. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.
Hashemian MN; Z-Mehrjardi H; Moghimi S; Tahvildari M; Mojazi-Amiri H
Ophthalmic Res; 2011; 46(1):50-4. PubMed ID: 21212709
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization.
Han YS; Lee JE; Jung JW; Lee JS
Graefes Arch Clin Exp Ophthalmol; 2009 Apr; 247(4):541-8. PubMed ID: 18953554
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.
Papathanassiou M; Theodossiadis PG; Liarakos VS; Rouvas A; Giamarellos-Bourboulis EJ; Vergados IA
Am J Ophthalmol; 2008 Mar; 145(3):424-431. PubMed ID: 18207123
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization.
Ozdemir O; Altintas O; Altintas L; Ozkan B; Akdag C; Yüksel N
Arq Bras Oftalmol; 2014 Aug; 77(4):209-13. PubMed ID: 25410169
[TBL] [Abstract][Full Text] [Related]
14. Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization.
Dratviman-Storobinsky O; Avraham-Lubin BCR; Hasanreisoglu M; Goldenberg-Cohen N
Mol Vis; 2009 Nov; 15():2326-38. PubMed ID: 19936307
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis.
Hosseini H; Nejabat M; Mehryar M; Yazdchi T; Sedaghat A; Noori F
Clin Exp Ophthalmol; 2007 Nov; 35(8):745-8. PubMed ID: 17997779
[TBL] [Abstract][Full Text] [Related]
16. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
Kim TI; Kim SW; Kim S; Kim T; Kim EK
Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
[TBL] [Abstract][Full Text] [Related]
18. Subconjunctival bevacizumab for corneal neovascularization.
Erdurmus M; Totan Y
Graefes Arch Clin Exp Ophthalmol; 2007 Oct; 245(10):1577-9. PubMed ID: 17458556
[TBL] [Abstract][Full Text] [Related]
19. Effect of bevacizumab on corneal neovascularization in experimental rabbit model.
Ahmed A; Berati H; Nalan A; Aylin S
Clin Exp Ophthalmol; 2009 Sep; 37(7):730-6. PubMed ID: 19788671
[TBL] [Abstract][Full Text] [Related]
20. The effect of bevacizumab on corneal neovascularization in rabbits.
Kim WJ; Jeong HO; Chung SK
Korean J Ophthalmol; 2010 Aug; 24(4):230-6. PubMed ID: 20714387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
